UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:CDK7_SLC30A5 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: CDK7_SLC30A5 | KinaseFusionDB ID: KFG1197 | FusionGDB2.0 ID: KFG1197 | Hgene | Tgene | Gene symbol | CDK7 | SLC30A5 | Gene ID | 1022 | 64924 | |
Gene name | cyclin dependent kinase 7 | solute carrier family 30 member 5 | ||||||||||
Synonyms | CAK|CAK1|CDKN7|HCAK|MO15|STK1|p39MO15 | ZNT5|ZNTL1|ZTL1|ZnT-5 | ||||||||||
Cytomap | 5q13.2 | 5q13.1-q13.2 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | cyclin-dependent kinase 739 KDa protein kinaseCDK-activating kinase 1TFIIH basal transcription factor complex kinase subunitcell division protein kinase 7cyclin-dependent kinase 7 (MO15 homolog, Xenopus laevis, cdk-activating kinase)homolog of Xenop | proton-coupled zinc antiporter SLC30A5solute carrier family 30 (zinc transporter), member 5zinc transporter ZTL1znT-like transporter 1 | ||||||||||
Modification date | 20240411 | 20240403 | ||||||||||
UniProtAcc | P50613 | Q8TAD4 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000256443, ENST00000514676, ENST00000502604, ENST00000513629, | ENST00000396591, ENST00000380860, ENST00000502979, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: CDK7 [Title/Abstract] AND SLC30A5 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CDK7 | GO:0006367 | transcription initiation at RNA polymerase II promoter | 7533895|8692841 |
Hgene | CDK7 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 9852112 |
Hgene | CDK7 | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 23622515 |
Tgene | SLC30A5 | GO:0006824 | cobalt ion transport | - |
Tgene | SLC30A5 | GO:0006829 | zinc ion transport | - |
Tgene | SLC30A5 | GO:1904257 | zinc ion import into Golgi lumen | 15994300 |
Kinase Fusion gene breakpoints across CDK7 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across SLC30A5 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
CCLE | CAL-72 | CDK7 | chr5 | 68531280 | SLC30A5 | chr5 | 68396634 |
CCLE | CAL-72 | CDK7 | chr5 | 68531280 | SLC30A5 | chr5 | 68398889 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:/:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
CDK7 | SLC30A5 |
FUNCTION: Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts (PubMed:9852112). Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, ECO:0000269|PubMed:9372954, ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}. | FUNCTION: Together with SLC30A6 forms a functional proton-coupled zinc ion antiporter mediating zinc entry into the lumen of organelles along the secretory pathway (PubMed:11904301, PubMed:15525635, PubMed:15994300, PubMed:19366695, PubMed:22529353). By contributing to zinc ion homeostasis within the early secretory pathway, regulates the activation and folding of enzymes like alkaline phosphatases and enzymes involved in phosphatidylinositol glycan anchor biosynthesis (PubMed:15525635, PubMed:15994300, PubMed:16636052, PubMed:35525268). Through the transport of zinc into secretory granules of pancreatic beta-cells, plays an important role in the storage and secretion of insulin (PubMed:11904301). {ECO:0000269|PubMed:11904301, ECO:0000269|PubMed:15525635, ECO:0000269|PubMed:15994300, ECO:0000269|PubMed:16636052, ECO:0000269|PubMed:19366695, ECO:0000269|PubMed:22529353, ECO:0000269|PubMed:35525268}.; FUNCTION: [Isoform 2]: Zinc ion:proton antiporter mediating influx and efflux of zinc at the plasma membrane. {ECO:0000269|PubMed:11937503, ECO:0000269|PubMed:17355957}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of CDK7_SLC30A5 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
CDK7 | P50613 | human | CDK11B | P21127 | T595 | GsPLKAytPVVVtLW | Pkinase |
CDK7 | P50613 | human | RB1 | P06400 | S780 | strPPtLsPIPHIPr | Rb_C |
CDK7 | P50613 | human | MCM2 | P49736 | S5 | ___MAEssEsFtMAs | |
CDK7 | P50613 | human | POU5F1 | Q01860 | S12 | LASDFAFsPPPGGGG | |
CDK7 | P50613 | human | CDK2 | P24941 | Y168 | HEVVtLWyRAPEILL | Pkinase |
CDK7 | P50613 | human | ESR1 | P03372 | S118 | LHPPPQLsPFLQPHG | Oest_recep |
CDK7 | P50613 | human | CDK6 | Q00534 | T177 | YSFQMALtSVVVTLW | Pkinase |
CDK7 | P50613 | human | OGFOD1 | Q8N543 | S256 | FEPPIPRsPHIPQDH | |
CDK7 | P50613 | human | TP53 | P04637 | S371 | AHssHLkskkGQsts | |
CDK7 | P50613 | human | SUPT5H | O00267 | T784 | MyGsGsrtPMyGsQt | |
CDK7 | P50613 | human | MCM2 | P49736 | S41 | RtDALtssPGRDLPP | |
CDK7 | P50613 | human | CDK9 | P50750 | S175 | FGLARAFsLAkNSQP | Pkinase |
CDK7 | P50613 | human | POLR2A | P24928 | S1616 | TPQSPSysPtsPsYS | RNA_pol_Rpb1_R |
CDK7 | P50613 | human | MED1 | Q15648 | T1457 | HsKsPAytPQNLDsE | |
CDK7 | P50613 | human | MCM2 | P49736 | S13 | EsFtMAssPAQRRRG | |
CDK7 | P50613 | human | RARA | P10276 | S77 | EIVPsPPsPPPLPRI | |
CDK7 | P50613 | human | XRN2 | Q9H0D6 | T439 | FtPsGILtPHALGsR | XRN_M |
CDK7 | P50613 | human | TP53 | P04637 | S376 | LkskkGQstsRHkkL | |
CDK7 | P50613 | human | E2F1 | Q01094 | T433 | DCDFGDLtPLDF___ | |
CDK7 | P50613 | human | SUPT5H | O00267 | T775 | tPMyGsQtPMyGsGs | |
CDK7 | P50613 | human | SUPT5H | O00267 | S782 | tPMyGsGsrtPMyGs | |
CDK7 | P50613 | human | CDK2 | P24941 | T160 | GVPVRtytHEVVtLW | Pkinase |
CDK7 | P50613 | human | SUPT5H | O00267 | S773 | GRtPMyGsQtPMyGs | |
CDK7 | P50613 | human | POLR2A | P24928 | S1621 | SysPtsPsYSPTSPS | RNA_pol_Rpb1_R |
CDK7 | P50613 | human | CDK4 | P11802 | T172 | YSYQMALtPVVVTLW | Pkinase |
CDK7 | P50613 | human | TP53 | P04637 | S378 | skkGQstsRHkkLMF | |
CDK7 | P50613 | human | SMAD1 | Q15797 | S206 | SSStYPHsPTSSDPG | |
CDK7 | P50613 | human | CDK1 | P06493 | T161 | GIPIRVytHEVVTLW | Pkinase |
CDK7 | P50613 | human | MCM2 | P49736 | S4 | ____MAEssEsFtMA | |
CDK7 | P50613 | human | TP53 | P04637 | S392 | FktEGPDsD______ | |
CDK7 | P50613 | human | PCGF6 | Q9BYE7 | S30 | LPPPPPVsPPALTPA | |
CDK7 | P50613 | human | TP53 | P04637 | S33 | LPENNVLsPLPsQAM | |
CDK7 | P50613 | human | POLR2A | P24928 | S1619 | SPSysPtsPsYSPTS | RNA_pol_Rpb1_R |
CDK7 | P50613 | human | MCM2 | P49736 | S108 | DVEELtAsQREAAER | MCM2_N |
CDK7 | P50613 | human | ERCC3 | P19447 | S90 | HIFLEAFsPVYKYAQ | Helicase_C_3 |
CDK7 | P50613 | human | RARG | P13631 | S79 | EMVPSsPsPPPPPRV | |
CDK7 | P50613 | human | CDK12 | Q9NYV4 | T893 | sEEsRPytNKVITLW | Pkinase |
CDK7 | P50613 | human | RB1 | P06400 | S807 | PGGNIyIsPLksPyk | Rb_C |
CDK7 | P50613 | human | MCM2 | P49736 | S40 | RRtDALtssPGRDLP | |
CDK7 | P50613 | human | MCM2 | P49736 | T59 | EsEGLLGtEGPLEEE | MCM2_N |
CDK7 | P50613 | human | MCM2 | P49736 | S53 | LPPFEDEsEGLLGtE | MCM2_N |
CDK7 | P50613 | human | MCM2 | P49736 | S139 | RRGLLyDsDEEDEER | MCM2_N |
CDK7 | P50613 | human | E2F1 | Q01094 | S403 | PEEFISLsPPHEALD | |
CDK7 | P50613 | human | RB1 | P06400 | S811 | IyIsPLksPykIsEG | Rb_C |
CDK7 | P50613 | human | RARG | P13631 | S77 | SEEMVPSsPsPPPPP | |
CDK7 | P50613 | human | HSPA5 | P11021 | T69 | tPsyVAFtPEGERLI | HSP70 |
CDK7 | P50613 | human | MCM2 | P49736 | S27 | GNDPLtssPGRssRR | |
CDK7 | P50613 | human | CDK2 | P24941 | S46 | tETEGVPsTAIREIS | Pkinase |
CDK7 | P50613 | human | CDK2 | P24941 | T165 | tytHEVVtLWyRAPE | Pkinase |
CDK7 | P50613 | human | POLR2A | P24928 | S1878 | sPKysPtsPtysPtt | RNA_pol_Rpb1_R |
CDK7 | P50613 | human | MCM2 | P49736 | S7 | _MAEssEsFtMAssP | |
CDK7 | P50613 | human | AR | P10275 | S516 | VSRVPYPsPTCVkSE | |
CDK7 | P50613 | human | NR5A1 | Q13285 | S203 | EYPEPYAsPPQPGLP |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
CDK7 | ID | Description | 0.00e+00 |
CDK7 | GO:1902893 | regulation of miRNA transcription | 3.10e-07 |
CDK7 | GO:0061614 | miRNA transcription | 3.10e-07 |
CDK7 | GO:2000628 | regulation of miRNA metabolic process | 6.68e-07 |
CDK7 | GO:0140747 | regulation of ncRNA transcription | 7.56e-07 |
CDK7 | GO:0010586 | miRNA metabolic process | 1.26e-06 |
CDK7 | GO:0048144 | fibroblast proliferation | 1.26e-06 |
CDK7 | GO:0006367 | transcription initiation at RNA polymerase II promoter | 1.42e-06 |
CDK7 | GO:1901990 | regulation of mitotic cell cycle phase transition | 2.63e-06 |
CDK7 | GO:0098781 | ncRNA transcription | 3.56e-06 |
CDK7 | GO:0000082 | G1/S transition of mitotic cell cycle | 4.61e-06 |
CDK7 | GO:0006352 | DNA-templated transcription initiation | 6.12e-06 |
CDK7 | GO:0044843 | cell cycle G1/S phase transition | 7.71e-06 |
CDK7 | GO:1901987 | regulation of cell cycle phase transition | 1.05e-05 |
CDK7 | GO:0035265 | organ growth | 1.05e-05 |
CDK7 | GO:0048145 | regulation of fibroblast proliferation | 1.05e-05 |
CDK7 | GO:0044772 | mitotic cell cycle phase transition | 1.15e-05 |
CDK7 | GO:0009755 | hormone-mediated signaling pathway | 1.51e-05 |
CDK7 | GO:0006368 | transcription elongation by RNA polymerase II | 3.14e-05 |
CDK7 | GO:1902749 | regulation of cell cycle G2/M phase transition | 3.14e-05 |
CDK7 | GO:0030850 | prostate gland development | 3.90e-05 |
CDK7 | GO:0048146 | positive regulation of fibroblast proliferation | 4.71e-05 |
CDK7 | GO:0006354 | DNA-templated transcription elongation | 5.75e-05 |
CDK7 | GO:0032786 | positive regulation of DNA-templated transcriptio | 1.50e-06 |
CDK7 | GO:0001655 | urogenital system development | 1.02e-04 |
CDK7 | GO:0071391 | cellular response to estrogen stimulus | 1.06e-04 |
CDK7 | GO:0060444 | branching involved in mammary gland duct morphogenesis | 1.40e-04 |
CDK7 | GO:1902894 | negative regulation of miRNA transcription | 2.33e-04 |
CDK7 | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 2.38e-04 |
CDK7 | GO:0060740 | prostate gland epithelium morphogenesis | 2.38e-04 |
CDK7 | GO:2000629 | negative regulation of miRNA metabolic process | 2.38e-04 |
CDK7 | GO:0030522 | intracellular receptor signaling pathway | 2.69e-04 |
CDK7 | GO:0060512 | prostate gland morphogenesis | 2.81e-04 |
CDK7 | GO:0060603 | mammary gland duct morphogenesis | 3.04e-04 |
CDK7 | GO:0045637 | regulation of myeloid cell differentiation | 3.36e-04 |
CDK7 | GO:0002064 | epithelial cell development | 3.36e-04 |
CDK7 | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 4.00e-04 |
CDK7 | GO:0032784 | regulation of DNA-templated transcription elongation | 4.04e-04 |
CDK7 | GO:0071353 | cellular response to interleukin-4 | 4.32e-04 |
CDK7 | GO:0045786 | negative regulation of cell cycle | 4.67e-04 |
CDK7 | GO:0002068 | glandular epithelial cell development | 4.67e-04 |
CDK7 | GO:0060218 | hematopoietic stem cell differentiation | 4.67e-04 |
CDK7 | GO:0070670 | response to interleukin-4 | 4.67e-04 |
CDK7 | GO:0065004 | protein-DNA complex assembly | 4.79e-04 |
CDK7 | GO:0048863 | stem cell differentiation | 5.27e-04 |
CDK7 | GO:0034502 | protein localization to chromosome | 5.48e-04 |
CDK7 | GO:0022612 | gland morphogenesis | 5.91e-04 |
CDK7 | GO:0006275 | regulation of DNA replication | 6.17e-04 |
CDK7 | GO:0048732 | gland development | 6.31e-04 |
CDK7 | GO:0000077 | DNA damage checkpoint signaling | 6.31e-04 |
Top |
Related Drugs to CDK7_SLC30A5 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning CDK7-SLC30A5 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to CDK7_SLC30A5 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |